EDIT Message Board Post 9191052 | Editas Medicine Inc.
home / stock / edit / edit message board
the1stbarbarian
(investorshub)
Posted on: Jul/15/2020 02:15:01
Source: investorshub
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156910302
I've heard they will publish preclinical data sometime
News, Short Squeeze, Breakout and More Instantly...
-
All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal ...
-
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post- renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative con...